Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
Researchers used physician-checked automated extraction of US clinical notes from 2020–2026 to describe BPC-157 use and reported outcomes.
Response direction was missing for 65.9%. Co-treatments, reporting biases and imperfect extraction prevent conclusions about effectiveness. Adverse events were probably under-reported.